Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $140.9 million.

  • UNITED THERAPEUTICS's Cash from Investing Activities rose 222.63% to $140.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$446.9 million, marking a year-over-year decrease of 176.72%. This contributed to the annual value of $417.2 million for FY2024, which is 157.98% up from last year.
  • UNITED THERAPEUTICS's Cash from Investing Activities amounted to $140.9 million in Q3 2025, which was up 146.98% from -$299.9 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Cash from Investing Activities registered a high of $735.3 million during Q1 2024, and its lowest value of -$359.2 million during Q1 2022.
  • Its 3-year average for Cash from Investing Activities is -$56.9 million, with a median of -$123.2 million in 2024.
  • As far as peak fluctuations go, UNITED THERAPEUTICS's Cash from Investing Activities slumped by 5,601.59% in 2022, and later spiked by 432.56% in 2024.
  • Over the past 5 years, UNITED THERAPEUTICS's Cash from Investing Activities (Quarterly) stood at -$195.8 million in 2021, then increased by 3.32% to -$189.3 million in 2022, then spiked by 122.24% to $42.1 million in 2023, then tumbled by 392.64% to -$123.2 million in 2024, then spiked by 222.63% to $140.9 million in 2025.
  • Its last three reported values are $140.9 million in Q3 2025, -$299.9 million for Q2 2025, and -$164.7 million during Q1 2025.